Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI

In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.

Acute Myeloid Leukemia Treatment (PDQ®) - PDQ Cancer Information

Treatment - Cancer Currents Blog - NCI

Revumenib: a new therapy for AML patients

Juan Manuel Pérez Huacuja Urista posted on LinkedIn

Therapeutic implications of menin inhibition in acute leukemias

Transforming NCI Cancer Clinical Trials - NCI

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant

Clinical Trial Results National Cancer Institute

Revumenib Shows Promise in Acute Leukemia - CancerConnect

Clinical Trial Results National Cancer Institute

Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI

Deepanjan Halder on LinkedIn: Revumenib (a Menin inhibitor) shows

Revumenib trial meets complete remission endpoint for acute

Primary Endpoint Met for Revumenib in Patients with AML and ALL

Summary of in vitro and in vivo data of given compounds and